Literature DB >> 16843451

A comparison between percutaneous and surgical transplantation of autologous skeletal myoblasts in a swine model of chronic myocardial infarction.

Juan José Gavira1, Maitane Perez-Ilzarbe, Gloria Abizanda, Alba García-Rodríguez, Josune Orbe, José Antonio Páramo, Miriam Belzunce, Gregorio Rábago, Joaquín Barba, Jesús Herreros, Angel Panizo, José A García de Jalón, Diego Martínez-Caro, Felipe Prósper.   

Abstract

OBJECTIVE: Our aim was to compare the efficacy of surgical versus percutaneous administration of skeletal myoblasts (SkM) in a swine model of chronic myocardial infarction and to determine the mechanism(s) involved in their beneficial effect.
METHODS: Two months after induction of myocardial infarction (MI), Goettingen miniature pigs underwent autologous SkM transplant either by direct surgical injection (n=6) or percutaneous access and intramyocardial delivery under fluoroscopic and echocardiographic guidance (n=6). Control animals received media alone (n=4). Functional analysis was performed by 2D echocardiography. Myoblast engraftment, in vivo cell differentiation, vessel formation, fibrosis, and the ratio between collagen type I/III deposition were analyzed in the infarct (IA) and non-infarct area (NIA) by immunohistochemistry.
RESULTS: Animals received a median of 407.55+/-115x10(6) BrdU-labeled autologous SkM. Myoblast transplant was associated with a statistically significant increase in left ventricular ejection fraction (p<0.01), increased vasculogenesis and decreased fibrosis (p<0.05), and reduced collagen type I/III ratio in the IA and NIA areas as compared with control animals. No differences were found between groups receiving SkM by percutaneous or surgical access.
CONCLUSIONS: Our results indicate that increased vasculogenesis and changes in matrix remodeling with decreased fibrosis are associated with the beneficial effect of SkM transplant in chronic MI. The equivalent benefit observed from surgical and percutaneous delivery has important clinical implications.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16843451     DOI: 10.1016/j.cardiores.2006.06.018

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  16 in total

Review 1.  Stem cells and cardiac repair: a critical analysis.

Authors:  Jonathan H Dinsmore; Nabil Dib
Journal:  J Cardiovasc Transl Res       Date:  2008-01-31       Impact factor: 4.132

Review 2.  Intramyocardial navigation and mapping for stem cell delivery.

Authors:  Peter J Psaltis; Andrew C W Zannettino; Stan Gronthos; Stephen G Worthley
Journal:  J Cardiovasc Transl Res       Date:  2009-10-23       Impact factor: 4.132

Review 3.  Stem cell differentiation: cardiac repair.

Authors:  Michael Rubart; Loren J Field
Journal:  Cells Tissues Organs       Date:  2007-12-20       Impact factor: 2.481

Review 4.  Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions.

Authors:  Santosh K Sanganalmath; Roberto Bolli
Journal:  Circ Res       Date:  2013-08-30       Impact factor: 17.367

Review 5.  "Second-generation" stem cells for cardiac repair.

Authors:  Alberto Núñez García; Ricardo Sanz-Ruiz; María Eugenia Fernández Santos; Francisco Fernández-Avilés
Journal:  World J Stem Cells       Date:  2015-03-26       Impact factor: 5.326

Review 6.  Stem cell therapy for chronic myocardial infarction.

Authors:  Manuel Mazo; Beatriz Pelacho; Felipe Prósper
Journal:  J Cardiovasc Transl Res       Date:  2010-01-21       Impact factor: 4.132

Review 7.  Skeletal myoblasts for cardiac repair.

Authors:  Shazia Durrani; Mikhail Konoplyannikov; Muhammad Ashraf; Khawaja Husnain Haider
Journal:  Regen Med       Date:  2010-11       Impact factor: 3.806

8.  Cardiac cell therapy trials: chronic myocardial infarction and congestive heart failure.

Authors:  Philippe Menasché
Journal:  J Cardiovasc Transl Res       Date:  2008-03-14       Impact factor: 4.132

9.  Percutaneous transendocardial delivery of self-complementary adeno-associated virus 6 achieves global cardiac gene transfer in canines.

Authors:  Lawrence T Bish; Meg M Sleeper; Benjamin Brainard; Stephen Cole; Nicholas Russell; Elanor Withnall; Jason Arndt; Caryn Reynolds; Ellen Davison; Julio Sanmiguel; Di Wu; Guangping Gao; James M Wilson; H L Sweeney
Journal:  Mol Ther       Date:  2008-09-23       Impact factor: 11.454

10.  MyoCell, a cell-based, autologous skeletal myoblast therapy for the treatment of cardiovascular diseases.

Authors:  Husnain Kh Haider; Ye Lei; Muhammad Ashraf
Journal:  Curr Opin Mol Ther       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.